Oramed Pharmaceuticals In... (ORMP)
NASDAQ: ORMP
· Real-Time Price · USD
2.06
-0.01 (-0.48%)
At close: Aug 20, 2025, 3:59 PM
Oramed Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 | Feb 28, 2021 |
Net Income | 13.26M | -7.64M | -10.2M | -19.64M | 9.2M | 1.53M | 13.3M | -3.28M | -1.31M | -3.61M | -8.74M | -7.25M | -11.07M | -10.71M | -8.1M | -7.19M | -5.63M | -4.61M |
Depreciation & Amortization | 30K | 30K | 31K | 52K | 54K | 56K | 53K | 54K | 52K | 37K | 17K | 15K | 15K | 11K | 12K | 19K | 28K | 28K |
Stock-Based Compensation | 800K | 2.19M | 1.23M | 301K | 1.23M | 1.29M | 1.37M | 852K | 1.82M | 173K | 2.55M | 3.05M | 1.88M | 4.03M | 1.71M | 985K | 982K | 411K |
Other Working Capital | 456K | -1.39M | -414K | 82K | -33K | 40K | 172K | 91K | -21K | -713K | -1.51M | 1.72M | 182K | -961K | -1.28M | -820K | -1.11M | 329K |
Other Non-Cash Items | -14.99M | 3.48M | 7.01M | 10.56M | -10.59M | -3.73M | -15.68M | -134K | -2.48M | -1.33M | -339K | -495K | 401K | -345K | -232K | -68K | 255K | 440K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2.61M | 2.53M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -2.64M | -1.57M | 15K | 1.63M | 2.18M | -626K | -452K | 1.82M | -3.25M | -816K | -1.55M | 2.44M | 279K | -2.11M | -295K | 108K | -1.28M | 480K |
Operating Cash Flow | -3.54M | -3.52M | -1.91M | -7.1M | 2.08M | -1.48M | -1.42M | -694K | -2.63M | -5.55M | -8.06M | -2.24M | -8.49M | -9.13M | -6.9M | -6.14M | -5.64M | -3.25M |
Capital Expenditures | -4K | -3K | -11K | -5K | n/a | -2K | -3K | -32K | -20K | -199K | -308K | -121K | -20K | -47K | n/a | -27K | -2K | -33K |
Cash Acquisitions | n/a | -7.25M | n/a | n/a | n/a | n/a | n/a | 75.09M | n/a | -6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -63.57M | n/a | -12M | -39.76M | n/a | -4M | n/a | -101M | -70.92M | -19M | -40.2M | -7.2M | -107M | n/a | -100M | -31.8M | -12.61M | -284K |
Sales Maturities Of Investments | 8.77M | 29.33M | 27.5M | -82.14M | 94.66M | 34M | 30M | 25.91M | 56.23M | 6M | 51.75M | 8.55M | 117.38M | 7.41M | 953K | 2.78M | 20.01M | -2.99M |
Other Investing Acitivies | -49K | 1.54M | -65K | 87.64M | n/a | n/a | n/a | n/a | n/a | 6M | 23K | 3K | n/a | n/a | -1K | n/a | -1K | 1K |
Investing Cash Flow | -54.85M | 23.62M | 15.42M | -34.26M | 94.66M | 30M | 30M | -75.12M | -14.71M | -13.2M | 11.26M | 1.23M | 10.36M | 7.36M | -99.05M | -29.05M | 7.39M | -3.31M |
Debt Repayment | n/a | n/a | 49.14M | n/a | -30.14M | -19M | -24.39M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | -372.79K | n/a | -1.19M | -1.29M | n/a | n/a | n/a | -2K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 1.79K | n/a | -49.15M | n/a | -406.07K | n/a | -611.57K | 74.55M | n/a | n/a | 20K | -64K | n/a | -677K | 623K | 16.17M | 2.99M | 3.75M |
Financial Cash Flow | -371K | n/a | -1.2M | -1.29M | -30.55M | -19M | -25M | 74.55M | 19.82M | 2.43M | 4.17M | 4.31M | -1K | 2.29M | 60.56M | 55.02M | 21.86M | 25.43M |
Net Cash Flow | -58.72M | 20.1M | 12.32M | -42.65M | 66.18M | 9.52M | 3.59M | -1.3M | -17.34M | -16.36M | 7.27M | 3.3M | 1.93M | 511K | -45.37M | 19.83M | 23.61M | 18.87M |
Free Cash Flow | -3.54M | -3.52M | -1.92M | -7.11M | 2.08M | -1.48M | -1.42M | -726K | -2.65M | -5.75M | -8.37M | -2.36M | -8.51M | -9.17M | -6.9M | -6.17M | -5.64M | -3.28M |